MKMasashi Kitano

Masashi Kitano

*This is an algorithmically generated author record based on publicly available information.

Masashi Kitano has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perioperative search for circulating tumor cells in patients undergoing prostate brachytherapy for clinically nonmetastatic prostate cancer

    by H. Tsumura, T. Satoh, K.-I. Tabata, H. Ishiyama, K. Takenaka, A. Sekiguchi, M. Kitano, K. Hayakawa, M. Iwamura

  • Open Access

    Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer

    by Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-Ichi Tabata, Kouji Takenaka, Akane Sekiguchi, Masaki Nakamura, Masashi Kitano, Kazushige Hayakawa, Masatsugu Iwamura

    Despite the absence of local prostate cancer recurrence, some patients develop distant metastases after prostate brachytherapy. We evaluate whether prostate brachytherapy procedures have a potential risk for hematogenous spillage of prostate cancer cells. Fifty-nine patients who were undergoing high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy participated in this prospective study. Thirty patients with high-risk or locally advanced cancer were treated with HDR brachytherapy after neoadjuvant androgen deprivation therapy (ADT). Twenty-nine patients with clinically localized cancer were treated with LDR brachytherapy without neoadjuvant ADT. Samples of peripheral blood were drawn in the operating room before insertion of needles (preoperative) and again immediately after the surgical manipulation (intraoperative). Blood samples of 7.5 mL were analyzed for circulating tumor cells (CTCs) using the CellSearch System. While no preoperative samples showed CTCs (0%), they were detected in intraoperative samples in 7 of the 59 patients (11.8%; preoperative vs. intraoperative, p = 0.012). Positive CTC status did not correlate with perioperative variables, including prostate-specific antigen (PSA) at diagnosis, use of neoadjuvant ADT, type of brachytherapy, Gleason score, and biopsy positive core rate. We detected CTCs from samples immediately after the surgical manipulation. Further study is needed to evaluate whether those CTCs actually can survive and proliferate at distant sites.


  • Comparison of Prophylactic Naftopidil, Tamsulosin, and Silodosin for 125I Brachytherapy–Induced Lower Urinary Tract Symptoms in Patients With Prostate Cancer: Randomized Controlled Trial

    by Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-Ichi Tabata, Shouko Kotani, Satoru Minamida, Masaki Kimura, Tetsuo Fujita, Kazumasa Matsumoto, Masashi Kitano, et al.


  • Cost comparison of curative therapies for localized prostate cancer in Japan: a single-institution experience

    by Takefumi Satoh, Hiromichi Ishiyama, Kazumasa Matsumoto, Ken-Ichi Tabata, Masashi Kitano, Masatsugu Iwamura, Masaki Kimura, Satoru Minamida, Hideyuki Yamashita, Daisuke Matsuda, et al.

    In addition to open surgery, curative therapies for prostate cancer now include endoscopic surgery and radiation therapies. Because of the expansion and subdivision of treatment methods for prostate cancer, the medical fee point schedule in Japan was revised in fiscal year 2006. We examined changes in medical income and expenditure after this revision of the medical fee system. We studied income and expenditure, after institution of the new medical fee schedule, for the five types of therapies for prostate cancer performed at our hospital: two surgical therapies (radical retropubic prostatectomy and laparoscopic prostatectomy) and three radiation therapies (three-dimensional conformal radiation therapy, 192Ir high-dose-rate brachytherapy, and 125I low-dose-rate brachytherapy). Low-dose-rate brachytherapy was found to be associated with a profit of yy199 per patient. Laparoscopic prostatectomy, a highly advanced medical treatment that the fee revision changed from a partially insured to an insured procedure, yielded a profit of yy75 672 per patient. However, high-dose-rate brachytherapy was associated with a loss of yy654 016 per patient. Given the loss in hospital income per patient undergoing high-dose-rate brachytherapy, the medical fee point system for this procedure should be reassessed.


  • Interactive-plan technique conquers the disadvantages of volume-reducing hormone therapy in 125I permanent implantation for localized prostate cancer

    by Hiromichi Ishiyama, Takefumi Satoh, Masashi Kitano, Shouko Kotani, Mineko Uemae, Shiro Baba, Kazushige Hayakawa

    The purpose of this study was to assess the impact of hormone therapy on post-implant dosimetry in patients in whom pre-plan and interactive-plan techniques were used for transperineal brachytherapy against prostatic cancer. The subjects comprised 244 patients treated using 125I seed implantation as monotherapy. The prescribed dose to the periphery of the prostate was 145 Gy. The pre-plan technique was used for 116 patients, and the interactiveplan technique for 128 patients. Hormone therapy was used in 71 patients (29.1%). The D90 (dose to 90% of prostate volume) of post-implant computed tomography (CT) analysis was assessed in both groups. In addition, the ratio of post-implant CT volume to preoperative ultrasonography (US) volume was assessed. In the pre-plan group, D90 was significantly lower for patients who received hormone therapy than for those who did not (P = 0.035). However, in the interactive-plan group, D90 did not differ between patients with and without hormone therapy (P = 0.467). The CT-to-US prostate volume ratio was 1.022 for patients who received hormone therapy and 0.960 for patients who did not (P = 0.021). Post-traumatic swelling following implantation is increased by cessation of hormone therapy and may reduce D90. However, the present results suggest that the interactive-plan technique overcomes this disadvantage of hormone therapy.


  • TEAM MEDICINE AT THE KITASATO UNIVERSITY HOSPITAL: CASE PRESENTATIONS AND FUTURE VISIONS

    by Meijin Nakayama, Rika Kurihara, Syunsuke Miyamoto, Masahiko Takeda, Satoru Yokobori, Tatsutoshi Suzuki, Kazuo Yao, Makito Okamoto, Yuzuru Niibe, Masashi Kitano, et al.

    • 1 June 2002
      • Vol. 62  (7) , 366-9

    [Relation between overall treatment time and local control of early glottic laryngeal cancer: comparison of six versus five times per week].

    by Masashi Kitano, Iku Nishiguchi, Yuki Aoki, Meijinn Nakayama, Hiromi Nagai, Hiroomi Takahashi, Makito Okamoto, Takashi Matsubayashi, Kazushige Hayakawa

    Local control probabilities of early glottic cancer were evaluated in relation to overall treatment time. From 1971 to 1996, 162 patients with T1 or T2 glottic cancer were treated with radiation therapy. Fifty-nine patients received irradiation six times per week from 1971 to 1987, and 103 patients received irradiation five times per week from 1987 to 1996. Local control rates were calculated by the Kaplan-Meier method, and the log-rank test was used for statistical analysis. The Cox proportional hazards model was used to evaluate the significance of prognostic variables on local control. The 5-year local control rates were 91.8% for T1 tumors and 78.1% for T2 tumors. There was a statistically significant difference in local control rates between the two groups (p = 0.009). The overall local control rate was 86.4% for both groups, showing no statistically significant difference. Multivariate analysis showed that T stage and overall treatment time were important parameters in relation to local control. In early glottic cancer, there is no significant difference in local control probabilities between irradiation six times per week and five times per week.